MAR D 4 2002 SS

1645 #10 Suns

Docket No.: 200701/1061

## THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Schultz et al.

**RECEIVED** 

Examiner: To Be Assigned

Serial No. :

09/757,992

MAR 0 6 2002

Art Unit:

Cnfrm. No.: 8517

7

**TECH CENTER 1600/2900** 

Art Unit: 1645

Filed

January 10, 2001

For

DETECTION OF SINGLE NUCLEOTIDE

**POLYMORPHISMS** 

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.97-1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In compliance with 37 C.F.R. §§ 1.97 and 1.98, applicants hereby bring to the attention of the U.S. Patent and Trademark Office the references listed on the attached PTO-1449 form. The pertinence of these references is indicated in the Written Opinion (copy enclosed) for the corresponding PCT application.

Pursuant to 37 C.F.R. § 1.97(b)(3), no fee is required. If additional fees are required, however, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 14-1138.

Respectfully submitted,

Date: February 27, 2002

NIXON PEABODY LLP

Clinton Square, P.O. Box 31051

Rochester, New York 14603 Telephone: (585) 263-1304

Facsimile: (585) 263-1600

Michael L. Goldman Registration No. 30,727

Certificate of Mailing - 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, Washington, D.C. 20231,

on the date below.

#16.27,2002 Date

KULK K. & Ruth R. Smith